With the development and regulatory approval of immune checkpoint inhibitors and adoptive
cell therapies, cancer immunotherapy has undergone a profound transformation over the …

The clinical responses observed following treatment with immune checkpoint inhibitors
(ICIs) support immunotherapy as a potential anticancer treatment. However, a large …

Immunotherapies have revolutionized the treatment paradigms of various types of cancers.
However, most of these immunomodulatory strategies focus on harnessing adaptive …

Anticancer agents continue to dominate the list of newly approved drugs, approximately half
of which are immunotherapies. This trend illustrates the considerable promise of cancer …

Immunotherapies such as immune checkpoint blockade (ICB) and adoptive cell therapy
(ACT) have revolutionized cancer treatment, especially in patients whose disease was …

Therapeutic cancer vaccines have undergone a resurgence in the past decade. A better
understanding of the breadth of tumour-associated antigens, the native immune response …

Myeloid-derived suppressor cells (MDSCs) are pathologically activated neutrophils and
monocytes with potent immunosuppressive activity. They are implicated in the regulation of …

Checkpoint inhibitors are being added to standard-of-care chemotherapy in multiple clinical
trials. Success has been reported in non–small and small cell lung carcinomas and …

Cancer immunotherapy aims to promote the activity of cytotoxic T lymphocytes (CTLs) within
a tumour, assist the priming of tumour-specific CTLs in lymphoid organs and establish …

Recent advances in several areas are rekindling interest and enabling progress in the
development of therapeutic cancer vaccines. These advances have been made in target …